StockData

SS Innovations International vs Stereotaxis

SSII and STXS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SSII and STXS compare

SS Innovations International is the larger company, worth 3.0 times as much as Stereotaxis ($267M against $88.4M).

SS Innovations International grew revenue faster over the last twelve months (89.7% versus −5.5% for Stereotaxis).

SS Innovations International keeps more of each dollar of sales as profit, with a net margin of −23.7% compared with −74.2% at Stereotaxis.

SS Innovations International scores higher on the StockData Score (8 against 7 for Stereotaxis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSSIISTXS
Size and price
Market cap$267M$88.4M
Share price$1.33$0.882
Change, 1 year−78.6%−60.3%
Change, 5 years–−85.2%
Beta (5Y)0.901.00
Employees81131
StockData Score
Total score8 (better)7
Valuation score2 (better)1
Growth score2 (better)1
Performance score2 (better)0
Health score25 (better)
Dividend score00
Valuation
P/S5.1×2.9× (better)
P/B5.0× (better)7.2×
FCF yield–−17.5%
Fair value$3.56$1.08
Margin of safety62.6% (better)18.0%
Growth
Revenue growth (TTM)89.7% (better)−5.5%
Revenue growth, 5Y average–4.0%
Profitability
Gross margin47.6%55.6% (better)
Operating margin−16.2% (better)−75.7%
Net margin−23.7% (better)−74.2%
FCF margin–−51.6%
Return on equity−26.1% (better)−326%
Return on invested capital−20.9%–
Financial health
Debt / equity–0.00
Interest coverage−7.4×–
Current ratio2.24 (better)1.42
Altman Z-score3.52 (better)−14.13
Piotroski F-score55
Dividends and buybacks
Buyback yield–−24.0%
Shareholder yield0.00% (better)−24.0%
Ownership
Held by institutions0.82%43.0%
Held by insiders76.7%20.3%
Insider net buying, 12 months$5.1M (better)$0
Short interest, % of float0.14%7.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.